Pioneering perspectives

Prof. Carlos Fernández de Larrea, Hospital Clinic Barcelona, Spain

Carlos Fernández de Larrea, MD, Hematologist and Principal Investigator, Hospital Clínic Barcelona, Spain
Carlos Fernández de Larrea, MD, Hematologist and Principal Investigator, Hospital Clínic Barcelona, Spain
Logo

Pioneering perspectives

"A key factor probably is trying to expand the point-of-care strategy to try to set a production unit in every hospital."

Prof. Carlos Fernández de Larrea, Hospital Clinic Barcelona, Spain

Further discussion

Scaling cell therapy access: the impact of multi site manufacturing

As one of seven centers contributing to the ARI0002h clinical trial, an academic B cell maturation antigen (BCMA)-targeted CAR T cell therapy trial for the treatment of relapsed/refractory multiple myeloma in Spain, the Hospital Clinic Barcelona and Prof. Carlos Fernández de Larrea, MD, Hematologist and Principal Investigator, have relied on the point-of-care (PoC) cell manufacturing approach.

PoC cell manufacturing, a decentralized approach where cell therapies are produced locally at or near hospitals, presents a transformative opportunity to expand access to life-saving treatments.1 Unlike the traditional centralized model, where possible disadvantages such as logistical challenges, limited flexibility, and high costs might limit patient access to cell therapies, PoC manufacturing networks could streamline tailored therapy production to deliver therapies faster to patients.2

As Prof. Fernández de Larrea notes, "A key factor probably is trying to expand the point-of-care strategy to try to set a production unit in every hospital." However, realizing this vision can lead to challenges such as obtaining GMP regulatory compliance, consistent quality controls (QC), and investing in advanced technologies.3

Furthermore, extending manufacturing to multiple sites demands the essential need for collaboration between hospitals, creating a robust network of treatment centers that share knowledge and work together to reach more patients. 4–6 Something Prof. Fernández de Larrea has highlighted as being a great need and benefit for his team, “We are very lucky in Spain because we have a strong network already in hematological malignancies…and that is a real advantage in the sense of samples and a network around protocols, etc.”.

As decentralized models, such as PoC manufacturing, continue to evolve, adaptability and interdisciplinary partnerships will be crucial in transforming personalized cell therapies from a complex challenge into a widely accessible reality through an efficient PoC manufacturing ecosystem.4–6

This is where advanced technologies such as the CliniMACS Prodigy® Platform, for seamless cell manufacturing, and the MACSQuant® Analyzer Portfolio, for automated analytics, can support decentralized models. Such advanced technologies standardize cell production, simplify technology transfer, and facilitate streamlined GMP compliance across multiple sites. As Prof. Fernández de Larrea highlights, “…the experience with a closed system as the CliniMACS Prodigy Platform…you can get all the information for every step on every specific product. That is a real advantage when you are designing [clinical trials] because it is something that is already proved.” By leveraging automation, digital integration, and standardized protocols, PoC manufacturing with the CliniMACS Prodigy Platform facilitates reproducibility and scalability in cell therapy production across a multitude of locations.

By fostering a culture of cooperation and innovation, we can overcome existing barriers and fully leverage the potential of multi site PoC manufacturing, revolutionizing the delivery of cell and gene therapies to bring transformative, personalized treatments to patients faster, more efficiently, and at a lower cost for those who need it most.

"We have to work together, not only we want, we have to work together to improve this field.”


Prof. Carlos Fernández de Larrea, Hospital Clinic Barcelona, Spain

Watch more interviews

You have previously chosen International as your location.
What do you want to do?